about
Manual removal of the placenta after vaginal delivery: an unsolved problem in obstetricsCombined thrombopoietin and platelet response to altitude in a patient with autoimmune thrombocytopenia.Long-term efficacy of postpartum intravenous iron therapy.Anemia and iron deficiency in pregnancyTechnical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings.Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome.Hemoglobinopathies, body iron stores and gestational diabetes mellitus.Characteristics and determinants of restless legs syndrome in pregnancy: a prospective study.Treatment of Anemia of Chronic Disease with True Iron Deficiency in Pregnancy.Variable efficacy of recombinant human erythropoietin in anemic pregnant women with different forms of heterozygous hemoglobinopathyThe problem of risk assessment and prophylaxis of venous thromboembolism in pregnancyEffect of altitude on thrombopoietin and the platelet count in healthy volunteersIs the sickle cell trait a risk factor in patients with type 2 diabetes mellitus?Treatment of midgestational placental haemorrhage with recombinant factor VIIaResponse to: Lavey, RS et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IB-IVA carcinoma of the cervix: a Southwest Oncology Group Study. Gynecol. Oncol. 95 (2004) 145-151Screening for beta-thalassaemia trait in anaemic pregnant womenIron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label studySelective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose aloneIron supplementation in pregnancyAuthor's reply to Steer
P50
Q26850927-4B716425-154A-4239-828F-DADAD7D2ED7EQ33360004-0644144C-5FA3-44A0-A86B-ACEAF4872FD9Q34546750-1959E807-EE55-4FA1-9DC0-893AC07218EEQ36210535-59A8778C-F0CC-4B3B-8206-CFDD2262CABCQ36655742-649292EF-3D90-46AF-BD9A-8F46CC420A2CQ38950208-C81348FC-5901-43A3-A724-E13B97139066Q46633515-900720DB-FFE5-44AD-8ECA-AD44287F4C0CQ48195079-13D7F042-3D3C-4A80-942B-54D7FD4AB0A1Q48214181-288B16FA-A874-44C6-AFEB-B9B7581D013EQ79374708-75B79B01-626F-4750-887C-B8E6E8627DF1Q80158281-7CF97AE2-6AC5-43AF-B363-9C2D7141468DQ81225776-3D55355B-2647-4A2E-8EE6-EB66C15E9524Q81297322-D059E599-B319-4DFA-A4BD-E0FCB42DE81FQ81607427-0D67BE5C-B9EC-42B1-B3B0-EF2FC1BFA64EQ81826950-D49EF199-E087-4CE0-B9FC-FA7914354794Q82716038-5C138C14-A565-4078-AD72-E7EB094ED198Q82892601-3C4A3A8A-E5EF-48B8-9247-A78146BE75E3Q84023239-2C2E0E06-55B0-404B-B47B-70DA36BB9F1AQ87075795-7B9B3B86-EC72-4F5D-A730-B9D800A8EE23Q87251900-ADE52D7B-93DF-400C-AB7B-604C2E5A3240
P50
description
researcher ORCID ID = 0000-0001-6768-2083
@en
wetenschapper
@nl
name
Alexander Krafft
@ast
Alexander Krafft
@en
Alexander Krafft
@es
Alexander Krafft
@nl
type
label
Alexander Krafft
@ast
Alexander Krafft
@en
Alexander Krafft
@es
Alexander Krafft
@nl
prefLabel
Alexander Krafft
@ast
Alexander Krafft
@en
Alexander Krafft
@es
Alexander Krafft
@nl
P31
P496
0000-0001-6768-2083